Team:Goettingen
From 2013.igem.org
m |
m |
||
Line 10: | Line 10: | ||
$("p").css("font-size","12pt"); | $("p").css("font-size","12pt"); | ||
}); | }); | ||
+ | $("#our-project").hide(); | ||
+ | $(".bkg").click(function(){ | ||
+ | $("#background").show(); | ||
+ | $("#our-project").hide(); | ||
+ | }); | ||
+ | $(".opr").click(function(){ | ||
+ | $("#our-project").show(); | ||
+ | $("#background").hide(); | ||
+ | }); | ||
}); | }); | ||
</script> | </script> | ||
<style> | <style> | ||
ul{list-style-type: none;list-style-image:url('');margin-left:1em} | ul{list-style-type: none;list-style-image:url('');margin-left:1em} | ||
+ | #p-logo{display:none} | ||
#content,#top-section{height:0px;padding:0 0 0 0;} | #content,#top-section{height:0px;padding:0 0 0 0;} | ||
+ | |||
body{background-color:#00334a; | body{background-color:#00334a; | ||
background-image:url('https://static.igem.org/mediawiki/2013/9/99/Test-fill.png'); | background-image:url('https://static.igem.org/mediawiki/2013/9/99/Test-fill.png'); | ||
Line 111: | Line 122: | ||
</div><!--close nav--> | </div><!--close nav--> | ||
<br /> | <br /> | ||
- | <div id="ctrl-p" class="box | + | |
+ | <div class="noprint"> | ||
+ | <div id="ctrl-p" class="box"> | ||
<h3 onclick="$('.ctrl-p').toggle('slow')" style="color:#8f0000;font-size:13pt;cursor:pointer">Control Panel:</h3> | <h3 onclick="$('.ctrl-p').toggle('slow')" style="color:#8f0000;font-size:13pt;cursor:pointer">Control Panel:</h3> | ||
<ul class="ctrl-p" style="font-size:12pt"> | <ul class="ctrl-p" style="font-size:12pt"> | ||
Line 119: | Line 132: | ||
</ul> | </ul> | ||
- | </div><!--close ctrl-p --> | + | </div><!--close ctrl-p --></div> |
Line 135: | Line 148: | ||
<div id="col-right"> | <div id="col-right"> | ||
+ | |||
<h1>The beast and its Achilles heel:<br / > | <h1>The beast and its Achilles heel:<br / > | ||
A novel target to fight multi-resistant pathogenic bacteria </h1> | A novel target to fight multi-resistant pathogenic bacteria </h1> | ||
- | + | <div id="background"> | |
<h2>The lack of novel antibiotics: the problem that we address </h2> | <h2>The lack of novel antibiotics: the problem that we address </h2> | ||
- | + | ||
<p>The discovery of penicillin by Alexander Fleming in 1928 and the broad application of antibiotics marked a major victory of mankind in the battle against infectious diseases. </p> | <p>The discovery of penicillin by Alexander Fleming in 1928 and the broad application of antibiotics marked a major victory of mankind in the battle against infectious diseases. </p> | ||
<p> However, shortly after the beginning of industrial penicillin production in 1942 some human pathogens already acquired resistance against penicillin and related antibiotics. </p> | <p> However, shortly after the beginning of industrial penicillin production in 1942 some human pathogens already acquired resistance against penicillin and related antibiotics. </p> | ||
Line 150: | Line 164: | ||
<br /> | <br /> | ||
<br /> | <br /> | ||
- | </div> | + | </div><!--close bkg --> |
- | < | + | <div id="our-project"> |
- | + | <h2>Our project: </h2> | |
+ | <img src="fig1.png" style="float:right;width:50%" /> | ||
<p>Our project is aimed at the development of a simple screening system, which allows the rapid identification and characterization of substances that disturb c-di-AMP homeostasis in pathogenic bacteria. </p> | <p>Our project is aimed at the development of a simple screening system, which allows the rapid identification and characterization of substances that disturb c-di-AMP homeostasis in pathogenic bacteria. </p> | ||
<p> The principle of how such a screening system could look like is illustrated in Figure 1. The screening system will be established in the non-pathogenic bacterium E. coli. </p> | <p> The principle of how such a screening system could look like is illustrated in Figure 1. The screening system will be established in the non-pathogenic bacterium E. coli. </p> | ||
Line 160: | Line 175: | ||
<p> First, c-di-AMP is not synthesized in E. coli. Thus, compounds that inhibit c-di-AMP synthesis will specifically inhibit growth of Gram-positive bacteria. Second, the use of a nonpathogenic E. coli strain, which is easy to cultivate will keep the costs very low.</p> | <p> First, c-di-AMP is not synthesized in E. coli. Thus, compounds that inhibit c-di-AMP synthesis will specifically inhibit growth of Gram-positive bacteria. Second, the use of a nonpathogenic E. coli strain, which is easy to cultivate will keep the costs very low.</p> | ||
<p> We are confident that our screening system will facilitate the identification of novel antibacterial substances because any change in the activity of the c-di-AMP-dependent promoter-reporter gene fusion, either by inhibition of c-di-AMP synthesis or by activation of DNA-binding activity of the transcription factor will indicate perturbation of c-di-AMP homeostasis. </p> | <p> We are confident that our screening system will facilitate the identification of novel antibacterial substances because any change in the activity of the c-di-AMP-dependent promoter-reporter gene fusion, either by inhibition of c-di-AMP synthesis or by activation of DNA-binding activity of the transcription factor will indicate perturbation of c-di-AMP homeostasis. </p> | ||
+ | </div><!-- close our-project--> | ||
</div><!--close col-right--> | </div><!--close col-right--> | ||
</html> | </html> |
Revision as of 12:21, 30 May 2013